“Incremental contribution by new products will help us grow in the US market,” said Sudhir Menon, ED & CFO of Torrent Pharma in an interview to CNBC-TV18.
He further added that clearance of facilities by the United States Food and Drug Administration (US FDA) is key for the company and expects US FDA re-inspection for Indrad and Dahej unit to happen soon.
Menon also believes that the second half of FY21 for the Indian market will be better than H1FY21 and sees growth in the Indian market every quarter.”
Speaking about debt, Menon said we would be reducing debt by Rs 1,000 crore by end of this year. “Our net debt to EBITDA stands at 1.7 times as of September 30,” he added.
For more, watch the video